Brief: Creative Medical Technology Announces Positive Top-Line Results For StemSpine Pilot Study
23/03/2022 13:23
March 23 (Reuters) - Creative Medical Technology Holdings
Inc CELZ.O :
* CREATIVE MEDICAL TECHNOLOGY ANNOUNCES POSITIVE TOP-LINE
RESULTS
FOR STEMSPINE® PILOT STUDY
* CREATIVE MEDICAL - NO SAFETY RELATED CONCERNS AT UP TO 2
YEARS
AND STEMSPINE PROCEDURE RESULTED IN EFFICACY RATE OF 87% IN
TREATED PATIENTS
Source text for Eikon: ID:nPn9QQHYNa
Further company coverage: CELZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM